Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Bonus Content Wall Street Loves FIGS—Why Do Price Targets Predict Pullback?Submitted by Jennifer Ryan Woods. Article Posted: 3/4/2026. 
Key Points - FIGS stock has surged nearly 260% over the past year, hitting a price not seen since shortly after its 2021 IPO.
- Q4 revenue topped $200 million—the company's best quarter ever—with scrubwear sales up 35% and international sales jumping 55%.
- Despite the rally and bullish analyst commentary, the consensus price target sits almost 30% below current levels.
- Special Report: [Sponsorship-Ad-6-Format3]
After a stunning plunge following its 2021 IPO, medical and lifestyle apparel company FIGS, Inc. (NYSE: FIGS) has roared back to levels it hasn't seen in nearly four years. The stock is trading above $17 and has surged almost 260% over the past year, including a 58% jump in the last month alone. The rally has been driven by strong earnings reports and a wave of bullish analyst commentary. Yet the consensus 12-month price target remains just $12.25—almost 30% below the current price. That gap raises the question: how much of FIGS' recovery is supported by fundamentals and how much is momentum? A look at the company's history and recent results offers some clues. Dr. Skousen: "Only 500 people today get the access code"
I've worked for the CIA. Met four US presidents.
But meeting Elon Musk face-to-face changed everything.
My research now leads me to believe he'll announce the SpaceX IPO on March 26, 2026.
I'm sharingan "access code" to grab a pre-IPO stake. But only with the first 500 people today. Click Here to See how to Get Your "SpaceX Access Code" Early investors saw a quick windfall after the May 2021 IPO, which priced at $22 per share and surged to $50 within a month as pandemic-driven demand for medical apparel spiked. As COVID-19 demand eased, shares reversed sharply and were trading below $8 within a year. FIGS then spent the following years mostly range-bound in the single digits, dipping below $4 in April 2025 before beginning a sustained move higher. Earnings Momentum Sparks Rally Steady gains after positive Q1 and Q2 2025 earnings reports set the stage for a breakout. The Q3 2025 results, released on Nov. 6, featured stronger-than-expected revenue growth, broad demand across core categories and healthy margins despite tariff pressures. The company raised full-year guidance for net revenue and adjusted EBITDA margins, prompting Wall Street applause. The stock rallied more than 30% in the week following the Q3 release, and Zacks Research upgraded the shares to Strong Buy from Hold. Momentum continued after the Q4 2025 earnings report on Feb. 26. FIGS posted a 33% jump in quarterly revenue—its best quarter yet—with sales topping $200 million. Management highlighted strength across the business on the earnings call, including growth in active customers and higher average order values. The company also noted the visibility boost from outfitting Team USA's medical team during the Winter Olympics. Scrubwear, FIGS' core segment that accounted for more than three-quarters of net revenue, grew 35% in the quarter, while international sales rose 55%. The fourth quarter capped a strong year: full-year net revenue reached a record $630 million, up 14% year-over-year. Despite tariff-related pressure on gross margins, profitability remained robust, with full-year adjusted EBITDA margin beating targets by more than 200 basis points. Analysts Applaud Earnings and Outlook FIGS issued an upbeat outlook for fiscal 2026, expecting net revenue growth of 10% to 12% and improvements in profitability targets. The company said it plans to expand into new international markets, prioritize growth opportunities across its businesses and continue its stock buyback program. Analysts responded with a flurry of upgrades and target changes. Barclays raised its rating to Strong Buy from Hold, KeyCorp moved to Overweight from Sector Weight with a $17 target, and Goldman Sachs shifted to Hold from Strong Sell. BTIG reiterated its Buy with a $15 target, and Telsey Advisory lifted its target to $15 from $9. FIGS Stock Pushes Past Price Targets FIGS' improving results are the clear catalyst for the recent move to four-year highs. Shares began climbing before the Q4 report, jumping nearly 14% in the session ahead of the release, then surged 24% on the first trading day after the results and gained another 10% the following day. As of March 4, the stock was trading above $17, which is more than double Morgan Stanley's $8 target issued in January and above KeyCorp's $17 target. The gap between bullish analyst sentiment and relatively conservative price targets suggests analysts appreciate FIGS' improving fundamentals but remain cautious about valuation. At current levels, the shares trade at a price-to-earnings ratio of nearly 90, indicating much of the company's expected growth may already be priced in. There are few publicly traded direct competitors to FIGS; however, broader lifestyle apparel names such as lululemon athletica inc. (NASDAQ: LULU) trade at much lower P/Es (lululemon is trading at a P/E of less than 12). The bottom line: investors are rewarding FIGS' turnaround, but skepticism remains about whether the stock can sustain this ascent or if a pullback may be in store.
| 
